SignalXSignalX

ADC Therapeutics SA (ADCT) 8-K Current Report: February 23, 2026

Filed: February 23, 2026
Health Care
Pharmaceutical Preparations
ADC Therapeutics SA Overview

ADC Therapeutics SA (ADCT) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

  • Item 1.01: Entry into a Material Definitive Agreement
  • Item 3.02: Unregistered Sales of Equity Securities

ADC Therapeutics SA 8-K Feb 23, 2026 Event Analysis

Item 1.01 · Entry into a Material Definitive Agreement

  • • HCR royalty deal amended: change-of-control payment slashed from up to $750M to $150M (before 2028) or $200M (after 2028)
  • • Post-acquisition royalty obligations can be bought out for $525M (by end 2029) or $750M (by end 2030), less prior royalties paid and CoC payment
  • • Amendment dramatically lowers upfront CoC cost, making ADCT a more attractive acquisition target by reducing deal friction
  • • HCR originally provided $300M in funding; amended terms structurally favor a cleaner M&A exit for a potential acquirer

Item 3.02 · Unregistered Sales of Equity Securities

  • • Warrants issued to HCR for 9,834,776 common shares at $3.8130/share, exercisable through Dec 31, 2030
  • • Lock-up on warrant transfers and underlying shares until Dec 31, 2027 — limits near-term selling pressure but caps HCR's flexibility
  • • Change-of-control trigger: if all-cash/marketable securities deal, warrants auto-exercise immediately prior to closing — protects HCR in M&A
  • • Company must file resale registration statement within 30 business days, creating future public float overhang of ~9.8M shares
  • • Cashless exercise option available, but Swiss law constraints on freely distributable equity may limit share delivery in some scenarios

Other ADC Therapeutics SA 8-K Filings

8-K Mar 10, 2026

Get deeper insights on ADC Therapeutics SA

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.